These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2664088)

  • 1. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.
    Cantello R; Aguggia M; Gilli M; Delsedime M; Chiardò Cutin I; Riccio A; Mutani R
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):724-31. PubMed ID: 2664088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinsonian patients report blunted subjective effects of methylphenidate.
    Persico AM; Reich S; Henningfield JE; Kuhar MJ; Uhl GR
    Exp Clin Psychopharmacol; 1998 Feb; 6(1):54-63. PubMed ID: 9526146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
    Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF
    J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate in mild depression: a double-blind controlled trial.
    Mattes JA
    J Clin Psychiatry; 1985 Dec; 46(12):525-7. PubMed ID: 3905773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mood and motor fluctuations in Parkinson's disease.
    Cantello R; Gianelli M; Mutani R
    Mov Disord; 1991; 6(2):186-8. PubMed ID: 1898451
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease.
    Evans AH; Lawrence AD; Lees AJ
    J Neurol Neurosurg Psychiatry; 2009 Mar; 80(3):267-72. PubMed ID: 18977820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment.
    Meyendorff E; Lerer B; Moore NC; Bow J; Gershon S
    Psychiatry Res; 1985 Dec; 16(4):303-8. PubMed ID: 4089058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
    Volkow ND; Wang GJ; Newcorn J; Telang F; Solanto MV; Fowler JS; Logan J; Ma Y; Schulz K; Pradhan K; Wong C; Swanson JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):932-40. PubMed ID: 17679638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haloperidol and lithium blocking of the mood response to intravenous methylphenidate.
    Wald D; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1978 Apr; 57(1):83-7. PubMed ID: 96473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intravenous cocaine are partially attenuated by haloperidol.
    Sherer MA; Kumor KM; Jaffe JH
    Psychiatry Res; 1989 Feb; 27(2):117-25. PubMed ID: 2652168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychologic and neuroendocrine response to methylphenidate.
    Brown WA
    Arch Gen Psychiatry; 1977 Sep; 34(9):1103-8. PubMed ID: 901139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography.
    Becker T; Becker G; Seufert J; Hofmann E; Lange KW; Naumann M; Lindner A; Reichmann H; Riederer P; Beckmann H; Reiners K
    J Neurol Neurosurg Psychiatry; 1997 Nov; 63(5):590-6. PubMed ID: 9408098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
    Moreau C; Delval A; Defebvre L; Dujardin K; Duhamel A; Petyt G; Vuillaume I; Corvol JC; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Sablonniere B; Azulay JP; Tison F; Rascol O; Vidailhet M; Destée A; Bloem BR; Bordet R; Devos D;
    Lancet Neurol; 2012 Jul; 11(7):589-96. PubMed ID: 22658702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes.
    Huey LY; Janowsky DS; Judd LL; Abrams A; Parker D; Clopton P
    Psychopharmacology (Berl); 1981; 73(2):161-4. PubMed ID: 6785807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
    Schrantee A; Tamminga HG; Bouziane C; Bottelier MA; Bron EE; Mutsaerts HJ; Zwinderman AH; Groote IR; Rombouts SA; Lindauer RJ; Klein S; Niessen WJ; Opmeer BC; Boer F; Lucassen PJ; Andersen SL; Geurts HM; Reneman L
    JAMA Psychiatry; 2016 Sep; 73(9):955-62. PubMed ID: 27487479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
    Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
    Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial.
    Kerr CW; Drake J; Milch RA; Brazeau DA; Skretny JA; Brazeau GA; Donnelly JP
    J Pain Symptom Manage; 2012 Jan; 43(1):68-77. PubMed ID: 22208450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.